Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt No Debt
CHRS's Cash to Debt is ranked higher than
67% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. CHRS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CHRS' s Cash to Debt Range Over the Past 10 Years
Min: 9.41  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset -0.03
CHRS's Equity to Asset is ranked lower than
94% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CHRS: -0.03 )
Ranked among companies with meaningful Equity to Asset only.
CHRS' s Equity to Asset Range Over the Past 10 Years
Min: -2.05  Med: -0.87 Max: 0.36
Current: -0.03
-2.05
0.36
F-Score: 3
Z-Score: -3.50
M-Score: -5.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -729.23
CHRS's Operating margin (%) is ranked lower than
76% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. CHRS: -729.23 )
Ranked among companies with meaningful Operating margin (%) only.
CHRS' s Operating margin (%) Range Over the Past 10 Years
Min: -2028.33  Med: -1018.80 Max: -207.94
Current: -729.23
-2028.33
-207.94
Net-margin (%) -743.18
CHRS's Net-margin (%) is ranked lower than
77% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. CHRS: -743.18 )
Ranked among companies with meaningful Net-margin (%) only.
CHRS' s Net-margin (%) Range Over the Past 10 Years
Min: -1949.65  Med: -1240.94 Max: -280.12
Current: -743.18
-1949.65
-280.12
ROE (%) -472.88
CHRS's ROE (%) is ranked lower than
97% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. CHRS: -472.88 )
Ranked among companies with meaningful ROE (%) only.
CHRS' s ROE (%) Range Over the Past 10 Years
Min: -736.9  Med: -736.90 Max: -736.9
Current: -472.88
ROA (%) -111.12
CHRS's ROA (%) is ranked lower than
89% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. CHRS: -111.12 )
Ranked among companies with meaningful ROA (%) only.
CHRS' s ROA (%) Range Over the Past 10 Years
Min: -145  Med: -111.74 Max: -74.26
Current: -111.12
-145
-74.26
ROC (Joel Greenblatt) (%) -3191.99
CHRS's ROC (Joel Greenblatt) (%) is ranked lower than
76% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. CHRS: -3191.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CHRS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2990.18  Med: -2887.81 Max: -2679.87
Current: -3191.99
-2990.18
-2679.87
» CHRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CHRS Guru Trades in

Q2 2015

CHRS Guru Trades in Q2 2015

Jim Simons 40,907 sh (New)
George Soros 127,600 sh (New)
» More
Q3 2015

CHRS Guru Trades in Q3 2015

Jim Simons 85,500 sh (+109.01%)
George Soros 127,600 sh (unchged)
» More
Q4 2015

CHRS Guru Trades in Q4 2015

George Soros 127,600 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CHRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 22.69
CHRS's P/S is ranked lower than
65% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. CHRS: 22.69 )
Ranked among companies with meaningful P/S only.
CHRS' s P/S Range Over the Past 10 Years
Min: 3.38  Med: 17.57 Max: 35.73
Current: 22.69
3.38
35.73
Current Ratio 1.86
CHRS's Current Ratio is ranked lower than
78% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. CHRS: 1.86 )
Ranked among companies with meaningful Current Ratio only.
CHRS' s Current Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.03 Max: 3.46
Current: 1.86
0.85
3.46
Quick Ratio 1.86
CHRS's Quick Ratio is ranked lower than
74% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. CHRS: 1.86 )
Ranked among companies with meaningful Quick Ratio only.
CHRS' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.03 Max: 3.46
Current: 1.86
0.85
3.46
Days Sales Outstanding 18.95
CHRS's Days Sales Outstanding is ranked higher than
85% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. CHRS: 18.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
CHRS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 18.95  Med: 29.37 Max: 36.88
Current: 18.95
18.95
36.88

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.29
CHRS's Price/Median PS Value is ranked lower than
70% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. CHRS: 1.29 )
Ranked among companies with meaningful Price/Median PS Value only.
CHRS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.25  Med: 0.93 Max: 1.6
Current: 1.29
0.25
1.6
Price/Graham Number 3.20
CHRS's Price/Graham Number is ranked lower than
61% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. CHRS: 3.20 )
Ranked among companies with meaningful Price/Graham Number only.
CHRS' s Price/Graham Number Range Over the Past 10 Years
Min: 3.95  Med: 3.95 Max: 3.95
Current: 3.2
Earnings Yield (Greenblatt) (%) -39.53
CHRS's Earnings Yield (Greenblatt) (%) is ranked lower than
84% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. CHRS: -39.53 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CHRS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -64.62  Med: 0.00 Max: 0
Current: -39.53
-64.62
0

More Statistics

Revenue(Mil) $30
EPS $ -5.99
Short Percentage of Float16.00%
52-Week Range $12.04 - 38.10
Shares Outstanding(Mil)39.10
» More Articles for CHRS

Headlines

Articles On GuruFocus.com
A Look at Pharma Company Dermira's Performance Mar 27 2015 

More From Other Websites
Coherus BioSciences to Present at Bank of America Merrill Lynch Health Care Conference on May 11 May 04 2016
Coherus BioSciences to Report First Quarter 2016 Financial Results on May 9 May 02 2016
Coherus BioSciences to Report First Quarter 2016 Financial Results on May 9 May 02 2016
Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : April... Apr 29 2016
New drugs that could save the US billions just got an approval that will change the face of Big... Apr 09 2016
Can the Rally in Coherus (CHRS) Shares Continue? Apr 01 2016
Coherus BioSciences to Present at Barclays Generic Pharmaceuticals Symposium on April 6 Mar 29 2016
Coherus BioSciences to Present at Barclays Generic Pharmaceuticals Symposium on April 6 Mar 29 2016
New Strong Buy Stocks for March 18th Mar 18 2016
Analyzing Arena Pharma's Return on Equity (ARNA, IMGN) Mar 08 2016
Biosimilars: Why You Can Expect Opportunity Ahead Mar 07 2016
Coherus BioSciences to Present at Barclays Global Healthcare Conference on March 16 Mar 07 2016
COHERUS BIOSCIENCES, INC. Financials Mar 05 2016
ETF’s with exposure to Coherus BioSciences, Inc. : March 4, 2016 Mar 04 2016
Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 03 2016
Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : March... Mar 03 2016
Edited Transcript of CHRS earnings conference call or presentation 29-Feb-16 9:30pm GMT Feb 29 2016
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of... Feb 29 2016
Coherus BioSciences reports 4Q loss Feb 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK